Scott Milton Myers

US Patent:

8420680, Apr 16, 2013

Filed:

Jun 30, 2008

Appl. No.:

12/165308

Inventors:

Dennis C. Liotta - Atlanta GA, US
James P. Snyder - Atlanta GA, US
Stephen F. Traynelis - Decatur GA, US
Lawrence Wilson - Atlanta GA, US
Cara Mosley - Atlanta GA, US
Raymond J. Dingledine - Atlanta GA, US
Yesim Altas Tahirovic - Decatur GA, US
Scott J. Myers - Atlanta GA, US

Assignee:

Emory University - Atlanta GA
NeurOp, Inc. - Atlanta GA

International Classification:

A61K 31/4166
A61K 31/421
A61K 31/495
C07D 241/04
C07D 263/18
C07D 233/08

US Classification:

514376, 548225, 5483111, 544358, 51425213, 514386

Abstract:

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided:.

US Patent:

20120302543, Nov 29, 2012

Filed:

Jun 13, 2012

Appl. No.:

13/495561

Inventors:

Ruppa Poornachary Kamalesh Babu - Alpharetta GA, US
Scott James Myers - Avondale Estates GA, US

International Classification:

A61K 31/4709
C07D 401/14
C07D 211/22
A61K 31/445
A61P 25/24
A61P 25/00
A61P 29/00
A61P 25/08
A61P 25/18
C07D 401/12
A61P 25/28

US Classification:

51421018, 546158, 514312, 546226, 514330

Abstract:

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of certain neurologic disorders, including disorders related to NMDA receptor activation, neuropsychiatric disorders, neurodegenerative disorders and other neurologic diseases, disorders and related conditions. The compounds are of the Formulas I and Ia-Ij as described herein.

US Patent:

20140031363, Jan 30, 2014

Filed:

Apr 15, 2013

Appl. No.:

13/862647

Inventors:

Dennis C. Liotta - Atlanta GA, US
James P. Snyder - Atlanta GA, US
Stephen F. Traynelis - Decatur GA, US
Lawrence Wilson - Atlanta GA, US
Cara Mosley - Atlanta GA, US
Raymond J. Dingledine - Atlanta GA, US
Scott Myers - Atlanta GA, US
Yesim Altas Tahirovic - Decatur GA, US

International Classification:

C07D 295/088
C07D 213/74
C07D 209/34
C07D 211/52
C07D 215/227
C07D 233/32
C07C 311/08
C07D 263/58

US Classification:

51425307, 514605, 51425503, 51425301, 51425402, 514327, 51425406, 51425409

Abstract:

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided:wherein:

US Patent:

20140148432, May 29, 2014

Filed:

Jan 31, 2014

Appl. No.:

14/169833

Inventors:

Ruppa Poornachary Kamalesh Babu - Alpharetta GA, US
Scott James Myers - Avondale Estates GA, US

International Classification:

A61K 31/4709
C07D 211/22
A61K 31/445
C07D 401/12
C07D 401/14

US Classification:

51421018, 514312, 514330

Abstract:

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of certain neurologic disorders, including disorders related to NMDA receptor activation, including neuropsychiatric disorders, neurodegenerative diorders and other neurologic diseases, disorders and conditions including stroke, brain injury, epilepsy, neuropsychiatric disorders, mood disorders, chronic pain and related conditions. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided:wherein Arand Arare independently substituted or unsubstituted aryl, heteroaryl or heterocycle;m, n, p and q are each independently 0, 1 or 2;A is a bond, CH, CH═CH, C≡C, NR, O or S;Each Ris independently selected from C-Calkyl, C-Ccycloalkyl, C-Chaloalkyl, OH, O-alkyl, O-aryl, SH, S-alkyl, fluoro, chloro, bromo, iodo, nitro, or cyano;Q is selected from CH, CHR, CR, NH, NR, O and S;Each Y is independently CRor CRCR;each R is independently selected from H, OH or alkyl, in particular Calkyl;X is O, S, or CH; andZ is OH, NRR, NRSO(C-Calkyl), NRC(O)NRR, NRC(S)NRR, NRCHO, NRC(O)(C-Calkyl), NRC(O)O(C-Calkyl), NR-dihydrothiazole, or NR-dihydroimidazole wherein each R, Rand Ris independently H, C-Calkyl or C-Caralkyl; or Z comes together with Artogether to form a substituted or unsubstituted heterocyclic ring system with Ar.